00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
22:34 , Apr 7, 2017 |  BioCentury  |  Finance

Right place, right time

The takeout of Vtesse Inc. by Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) filled gaps for each company while giving Vtesse investors an exit and a share of any upside. The Vtesse team will get the resources it...
07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

R-Tech Ueno, Sucampo deal

Sucampo launched a tender offer to acquire R-Tech for Y33 billion ($273.9 million). R-Tech manufactures constipation drug Amitiza lubiprostone for Sucampo and Sucampo’s commercialization partners, including Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), Mylan N.V....
00:36 , Aug 27, 2015 |  BC Extra  |  Company News

Sucampo launches tender offer to acquire R-Tech Ueno

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) launched a tender offer to acquire R-Tech Ueno Ltd. (JASDAQ:4573) for Y33 billion ($273.9 million). R-Tech manufactures constipation drug Amitiza lubiprostone for Sucampo and its commercialization partners including Takeda Pharmaceutical Co....
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Sucampo, Gloria Pharmaceuticals deal

Sucampo granted Harbin Gloria exclusive rights to develop and commercialize Amitiza lubiprostone in China for 13 years. Sucampo will provide Gloria with Amitiza at an undisclosed supply price. Sucampo will receive a $1 million upfront...
07:00 , Jun 1, 2015 |  BioCentury  |  Regulation

Formalizing function

FDA agreed with patients at a workshop on functional GI disorders that patient-reported outcomes measures should tease out the relationship between symptom relief and corresponding quality of life. But doing so presents a catch-22 for...
07:00 , May 11, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...